-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-520771-59-00
4
2026-02-03
Atopic Dermatitis
-
2025-523088-39-00
1
2026-01-28
Advanced Solid Tumors
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2025-522862-58-00
5
2026-01-09
Locally advanced unresectable or metastatic gastric or gastroesophagea
-
2025-522680-14-00
2
2025-12-23
Chronic Graft-versus-Host Disease
-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2025-520742-29-00
5
2025-12-19
Low-risk renal transplant patients
-
2025-521661-27-00
10
2025-12-19
Primary Membranous Nephropathy
-
2024-518288-37-00
3
2025-12-18
Lupus Nephritis
-
2025-522203-23-00
7
2025-12-18
Advanced Solid Tumors
-
2024-513008-32-00
4
2025-12-17
Adenocarcinoma of the gastroesophageal junction
-
2025-520825-19-00
5
2025-12-16
IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as
Ber
-
2025-522395-92-00
5
2025-12-15
metastatic oeso-gastric adenocarcinoma
-
2024-518465-10-00
4
2025-12-12
Multiple Autoimmune Glomerular Diseases
-
2024-513619-28-00
1
2025-12-11
Clear Cell Renal Cell Carcinoma
-
2024-515201-26-00
4
2025-12-09
Small cell lung cancer (SCLC)
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-518528-54-00
1
2025-12-02
Active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), o
-
2025-521706-17-00
4
2025-11-25
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
-
2024-516602-28-00
7
2025-11-21
Advanced Solid Tumors
-
2025-520555-89-00
5
2025-11-14
Metastatic castration-resistant prostate cancer (mCRPC)
-
2024-511236-27-00
7
2025-11-12
High grade serous or endometroid ovarian cancer
-
2023-508612-29-00
5
2025-11-07
Advanced Melanoma